medigraphic.com
SPANISH

16 de abril

ISSN 1729-6935 (Electronic)
16 de abril
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • Policies
  • ABOUT US
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2021, Number 282

<< Back Next >>

16 de abril 2021; 60 (282)

Clinical-epidemiological characterization in patients diagnosed with immune thrombocytopenic purpura at ''Vladimir Ilich Lenin'' General Hospital

Hernández-Velázquez FM, Fernández-Sarmiento DM, Santiesteban-Rodríguez BC, Pizarro-Hechevarría RJ
Full text How to cite this article

Language: Spanish
References: 15
Page: 1-5
PDF size: 461.55 Kb.


Key words:

Autoimmunity, Bleeding, Thrombocytopenia, Thrombocytopenic purpura.

ABSTRACT

Introduction: immune thrombocytopenic purpura is a bleeding disorder characterized by an isolated decrease in platelets, not associated to any other recognizable pathology. The management of immune thrombocytopenia is a matter of discussion regarding its evolution, diagnosis, prognosis and treatment.
Objective: to characterize the patients diagnosed with immune thrombocytopenic purpura clinically and epidemiologically at “Vladimir Ilich Lenin” General Hospital, from 2015 to 2020.
Method: an observational, descriptive, cross-sectional study was carried out at the “Vladimir Ilich Lenin” General Hospital, in the province of Holguín, Cuba. The study period ranged from 2015 to 2020. The universe consisted of 30 patients who met the inclusion criteria of the research. The entire universe was studied.
Results: female sex (63,3 %) and the age group from 40 to 49 years old (46,7 %) predominated. At the time of admission, 43,3 % of the studied patients presented slight bleeding, and 46,7 %, a platelet count with moderate thrombocytopenia. 56,7 % had a complete response to first-line treatment.
Conclusions: female patients, between 40 to 49 years old predominated with mild bleeding and moderate thrombocytopenia at the time of admission. The largest number of patients had a complete response to first-line treatment and progressed to chronicity.


REFERENCES

  1. Escamilla Gutiérrez ML, OrdazCarrillo MI. Intervención cognitivo-conductual en un caso deenojo relacionado con púrpuratrombocitopénica inmune. Rev SaludEduc [Internet]. 2020 [citado 31/08/2021]; 8(16):33-7. Disponibleen: https://repository.uaeh.edu.mx/revistas/index.php/ICSA/article/view/4962

  2. Beligoy LE. Trombocitopeniainmune persistente y crónica deladulto: opciones terapéuticas. RevHematología [Internet]. 2018 [citado 31/08/2021]; 22(ext):54-61.Disponible en: http://revistahematologia.com.ar/index.php/Revista/article/view/56/43

  3. Arepally GM. Heparin-inducedthrombocytopenia. ArteriosclerThromb Vasc Biol [Internet]. 2021[citado 31/08/2021]; 41:141-152.Disponible en: https://www.ahajournals.org/doi/full/10.1161/ATVBAHA.120.315445

  4. Terrell DR, Neunert CE, Cooper N,Heitink-Pollé KM, Kruse C, ImbachP, et al. Immune Thrombocytopenia(ITP): Current Limitations inPatient Management. Medicina(Kaunas) [Internet]. 2020 [citado31/08/2021]; 56(12):667. Disponibleen: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761470/

  5. Matzdorff A, Meyer O, OstermannH, Kiefel V, Eberl W, KühneT, et al. Immune Thrombocytopenia– Current Diagnostics andTherapy: Recommendations ofa Joint Working Group of DGHO,ÖGHO, SGH, GPOH, and DGTI. OncolRes Treat [Internet]. 2018 [citado31/08/2021]; 41(suppl5):1–30.Disponible en: https://pubmed.ncbi.nlm.nih.gov/30235458/ https://www.karger.com/Article/Pdf/492187

  6. López Rivera VE. Púrpura Trombocitopénicainmune: Respuestaal tratamiento con Metilprednisolonaen pacientes que ingresaronal Hospital Manuel de Jesús Rivera“La Mascota” en el período 01de Enero 2014 al 31 de Diciembredel 2016. [Tesis]. [Internet]. Nicaragua:Universidad Nacional Autónomade Nicaragua. FacultadDe Ciencias Médicas UNAN Managua;2017. [citado 31/08/2021].Disponible en: https://repositorio.unan.edu.ni/8162/1/98676.pdf

  7. Silva CL, Grando AC. Complicationsof idiopathic thrombocytopenicpurpura in pregnancy:a review of literature. J Bras PatolMed Lab [Internet]. 2021 [citado31/08/2021]; 57(1):1-8. Disponibleen: https://www.scielo.br/j/jbpml/a/BGbTfj3hBHbVTt3zgFxbBmt/#

  8. Donato H. PTI. “Según pasanlos años”. Rev Hematología [Internet].2017 [citado 31 31/08/2021];21(ext23):137–51. Disponible en:http://www.sah.org.ar/revista/numeros/vol21/extra3/21-vol21-extra_noviembre.pdf

  9. León Mondragón EK, PereyraRamírez JG. Características clínicas,laboratoriales y evoluciónde trombocitopenia inmune enpacientes adultos atendidos enHospital Regional Lambayequey Hospital Docente Las Mercedes,2013 – 2017. [Tesis]. [Internet].Perú: Universidad Nacional“Pedro Ruiz Gallo”. Facultad deMedicina Humana; 2019 [citado31/08/2021]. Disponible en: https://repositorio.unprg.edu.pe/handle/20.500.12893/3883

  10. Nina García NM, HuaritaH. Púrpura TrombocitopénicaIdiopática en adultos: experienciaen un hospital de tercer nivel,La Paz, Bolivia. Rev Cient CiencMéd [Internet]. 2019 [citado31/08/2021]; 22(2):7-14. Disponibleen: http://www.scielo.org.bo/scielo.php?script=sci_arttext&pid=S1817-74332019000200002&lng=es.

  11. Donato H, Bacciedoni V, RapettiMC, Elena G, Lavergne M,Rossi N, et al. Trombocitopeniainmune. Guía de diagnóstico y tratamiento.Arch Argent Pediatr [Internet].2019 [citado 31/08/2021];117(supl6):243-254. Disponible en:https://www.sap.org.ar/uploads/consensos/consensos_trombocitopenia-inmune-guia-de-diagnostico-y-tratamiento-91.pdf

  12. Onisâi M, Vlădăreanu Am,Spînu A, Găman M, Bumbea H.Idiopathic thrombocytopenic purpura(ITP) – new era for an olddisease. ROM J INTERN MED [Internet].2019 [citado 31/08/2021];57(4):273-283. Disponible en: https://sciendo.com/pdf/10.2478/rjim-2019-0014

  13. Palmezano Díaz JM, FigueroaPineda CL, Rodríguez Amaya RM,Plazas Rey LK. Prevalencia y caracterizaciónde las enfermedadesautoinmunitarias en pacientesmayores de 13 años en un hospitalde Colombia. Med Interna Méx [Internet].2018 [citado 31/08/2021];34(4):522-535. Disponible en:http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0186-48662018000400003&lng=es

  14. Palmezano Diaz JM, FigueroaPineda CL, Amaya RM, RengifoQuintero LJ, Mogollón Moreno YD,Moreno Useche LD, et al. CaracterizaciónClínica de los Pacientescon Púrpura TrombocitopénicaInmune en un Hospital Universitarioen Colombia. Rev Med [Internet].2018 [citado 31/08/2021];40(1):108-109. Disponible en:https://revistamedicina.net/ojsanm/index.php/Medicina/article/view/1299

  15. Petro López K, Sgromo M, BoedoL, Mandrile A, Almeida L. Púrpuratrombocitopénica inmune:tratamiento de segunda línea, experienciaen el Sanatorio Güemescentrada en trombomiméticos.Rev Hematología [Internet]. 2020[citado 31/08/2021]; 24(3):19-24. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7863748




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

16 de abril. 2021;60